SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease

Published: 20 July 2021

Views:
22120
Likes:
7

Views:
22120
Likes:
7
Share:

Now Playing
Part 7 | Session 2 of 3
Keynote Lecture - SGLT2 Inhibitors for Heart Failure: The New Standard of Care
Milton Packer

Up Next
Part 7 | Session 3 Panel Discussion
Stefan Anker, Mark Petrie, Marco Metra

Part 8 | Session 1 Welcome and Introduction
Mark Petrie, Deepak L Bhatt
Part 8 | Session 2 Soloist Trial Overview
Deepak L Bhatt
Part 8 | Session 3 Discussion
Mark Petrie, Deepak L Bhatt

Part 9 | Session 1 Managing Patients with Comorbidities (T2D & CKD)
Paola Fioretto, Katherine Tuttle

Part 10 | Session 1 Interdisciplinary Collaboration and Care Transitions
Subodh Verma

Part 1 | Session 1 Welcome and Introduction Stefan Anker, Shelley Zieroth

Part 1 | Session 2 SGLT2 Inhibitors for Patients with Diabetes and an Increased CV Risk: How The Success Story Started Bernard Zinman

Part 1 | Session 3 SGLT2 Inhibitors: Evolution from Glucose Lowering to Cardiorenal Protection Milton Packer

Part 1 | Session 4 SGLT2 Inhibitors in Cardiology Indications: The Data John JV McMurray

Part 1 | Session 5 SGLT2 Inhibitors in Chronic Kidney Disease: The Data Katherine Tuttle

Part 1 | Session 6 Panel Discussion Stefan Anker, Shelley Zieroth, Andrew JS Coats, Bernard Zinman, John JV McMurray, Katherine Tuttle

Part 2 | Session 1 Place of SGLT2 Inhibitors in the Heart Failure Treatment Algorithm Andrew JS Coats

Part 2 | Session 2 SGLT2 Inhibitors: Safety Considerations Gerasimos Filippatos

Part 2 | Session 3 How to Use SGLT2 Inhibitors in Daily Practice Javed Butler

Part 2 | Session 4 Panel Discussion Andrew JS Coats, Gerasimos Filippatos, Shelley Zieroth, Stefan Anker

Part 3 | Session 1 Totality of Evidence for the Cardiorenal Patient Alice Cheng, Andrew JS Coats

Part 3 | Session 2 Discussion Alice Cheng, Andrew JS Coats

Part 4 | Session 1 Welcome and Introduction Shelley Zieroth, John Spertus

Part 4 | Session 2 KCCQ Score Overview and Discussion Shelley Zieroth, John Spertus

Part 5 | Session 1 Welcome and Introduction Gerasimos Filippatos, Giuseppe Rosano

Part 5 | Session 2 SGLT2i in the Elderly and Vulnerable Patients Gerasimos Filippatos

Part 5 | Session 3 Discussion Giuseppe Rosano, Gerasimos Filippatos

Part 6 | Session 1 Welcome and Introduction Stefan Anker, Mark Petrie

Part 6 | Session 2 How do SGLT2 Inhibitors Bring About Cardiorenal Benefits? Subodh Verma

Part 6 | Session 3 Totality of Evidence in Heart Failure Deepak L Bhatt

Part 6 | Session 4 Trial Results Coming Out Soon Stefan Anker

Part 6 | Session 5 Heart Failure Guidelines Marco Metra

Part 6 | Session 6 Panel Discussion Stefan Anker, Mark Petrie, Deepak L Bhatt, Marco Metra

Part 7 | Session 1 Welcome and Introduction Stefan Anker, Mark Petrie, Marco Metra

Average (ratings)

No ratings

Your rating

Overview

Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders.

The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.

In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities. Audience questions were submitted throughout and were addressed by the panel experts.

Educational Objectives

SGLT2 Inhibition in Cardiorenal Disease

Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
Apply findings from clinical trials into clinical practice
Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
Evaluate the safety and cardiorenal benefits of glucose-lowering agents
Implement the new guidelines of the HFA of the ESC in clinical practice

Target Audience

Cardiologists
Nephrologists
Endocrinologists

More from this programme

Part 1

State of the Art 1

6 sessions
Welcome and Introduction	Watch now
SGLT2 Inhibitors for Patients with Diabetes and an Increased CV Risk: How The Success Story Started	Watch now
SGLT2 Inhibitors: Evolution from Glucose Lowering to Cardiorenal Protection	Watch now
SGLT2 Inhibitors in Cardiology Indications: The Data	Watch now
SGLT2 Inhibitors in Chronic Kidney Disease: The Data	Watch now
Panel Discussion	Watch now

Part 2

SGLT2 Inhibitors in Heart Failure: A Practical Approach

Industry Satellite Symposium supported by the Boehringer Ingelheim and Lilly alliance

4 sessions
Place of SGLT2 Inhibitors in the Heart Failure Treatment Algorithm	Watch now
SGLT2 Inhibitors: Safety Considerations	Watch now
How to Use SGLT2 Inhibitors in Daily Practice	Watch now
Panel Discussion	Watch now

Part 3

Meet The Expert: Implications for Clinical Practice - Breakout 1

Totality of Evidence for the Cardiorenal Patient - discussion with Alice Cheung and Andrew Coats. Session supported by an unrestricted grant from AstraZeneca

2 sessions
Totality of Evidence for the Cardiorenal Patient	Watch now
Discussion	Watch now

Part 4

Meet The Expert: Implications for Clinical Practice - Breakout 2

SGLT2i and QoL Improvement - discussion with Shelley Zieroth and John Spertus.

2 sessions
Welcome and Introduction	Watch now
KCCQ Score Overview and Discussion	Watch now

Part 5

Meet The Expert: Implications for Clinical Practice - Breakout 3

Age groups and vulnerable patients with Gerasimos Filippatos and Giuseppe Rosano.

3 sessions
Welcome and Introduction	Watch now
SGLT2i in the Elderly and Vulnerable Patients	Watch now
Discussion	Watch now

Part 6

State of the Art 2

6 sessions
Welcome and Introduction	Watch now
How do SGLT2 Inhibitors Bring About Cardiorenal Benefits?	Watch now
Totality of Evidence in Heart Failure	Watch now
Trial Results Coming Out Soon	Watch now
Heart Failure Guidelines	Watch now
Panel Discussion	Watch now

Part 7

SGLT2 Inhibitors for Heart Failure: The New Standard of Care

Industry Satellite Symposium supported by the Boehringer Ingelheim and Lilly alliance

3 sessions
Welcome and Introduction	Watch now
Keynote Lecture - SGLT2 Inhibitors for Heart Failure: The New Standard of Care	Watch now
Panel Discussion	Watch now

Part 8

Meet The Expert: Implications for Clinical Practice - Breakout 4

Early Treatment Initiation in the Hospital Setting - discussion with Marc Petrie and Deepak Bhatt. Session supported by an unrestricted grant from AstraZeneca

3 sessions
Welcome and Introduction	Watch now
Soloist Trial Overview	Watch now
Discussion	Watch now

Part 9

Meet The Expert: Implications for Clinical Practice - Breakout 5

Managing Patients with Comorbidities (T2D & CKD) - discussion with Paola Fioretto and Katherine Tuttle. Session supported by an unrestricted grant from AstraZeneca

1 session
Managing Patients with Comorbidities (T2D & CKD)	Watch now

Part 10

Meet The Expert: Implications for Clinical Practice - Breakout 6

Interdisciplinary Collaboration and Care Transitions - discussion with Subodh Verma. Session supported by an unrestricted grant from AstraZeneca

1 session
Interdisciplinary Collaboration and Care Transitions	Watch now

Faculty Biographies

Milton Packer

Distinguished Scholar in Cardiovascular Science

Personal History

Dr Milton Packer was born to Polish immigrants in 1951 and raised in Philadelphia, US. Prior to studying medicine, he was politically active in the 1960s. In his words: “The focus of my upbringing was education, but the major guiding principle in my childhood years (and throughout my entire life) was an uncompromising sense of justice. I was always imbued with the need to strive for and defend the truth.” He began his career in cardiology during a pivotal time for the field, just as interventional cardiology and

View full profile